Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akebia Therapeutics
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female Japanese participants ≥20 years of age
Receiving chronic maintenance hemodialysis for end-stage kidney disease
Hemoglobin (Hb) \<10.0 grams per deciliter (g/dL)
You may not be if
Anemia due to a cause other than chronic kidney disease (CKD) or presence of active bleeding or recent blood loss
Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
Red blood cell transfusion within 4 weeks prior to or during screening
Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation
Clareo Health | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
